Efficacy of the Investigational Echinocandin ASP9726 in a Guinea Pig Model of Invasive Pulmonary Aspergillosis

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2015-03-09

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/AAC.04857-14PMID 25753643PMCID PMC4394786
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Combination Antifungal Therapy for Invasive Aspergillosis

  2015cited by this paper
• Synthesis and Antifungal Activity of ASP9726, a Novel Echinocandin with Potent Aspergillus hyphal Growth Inhibition.

  2014cited by this paper
• Synthesis and antifungal activity of ASP9726, a novel echinocandin with potent Aspergillus hyphal growth inhibition.

  2014cited by this paper
• Interlaboratory and Interstudy Reproducibility of a Novel Lateral-Flow Device and Influence of Antifungal Therapy on Detection of Invasive Pulmonary Aspergillosis

  2012cited by this paper
• Strain-Dependent Variation in 18S Ribosomal DNA Copy Numbers in Aspergillus fumigatus

  2009cited by this paper
• Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis

  2009cited by this paper
• Paradoxical echinocandin activity: a limited in vitro phenomenon?

  2009cited by this paper
• Assessment of Aspergillus fumigatus Burden in Pulmonary Tissue of Guinea Pigs by Quantitative PCR, Galactomannan Enzyme Immunoassay, and Quantitative Culture

  2008influential reference
• Reference method for broth dilution antifungal susceptibility testing of filamentous fungi : Approved standard

  2008cited by this paper
• Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.

  2007cited by this paper
• Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial.

  2007cited by this paper
• Assessment of Serum (1→3)-β-d-Glucan Concentration as a Measure of Disease Burden in a Murine Model of Invasive Pulmonary Aspergillosis

  2007cited by this paper
• Attenuation of echinocandin activity at elevated concentrations: a review of the paradoxical effect

  2007cited by this paper
• Anidulafungin versus fluconazole for invasive candidiasis.

  2007cited by this paper
• Standardization of an Experimental Murine Model of Invasive Pulmonary Aspergillosis

  2006cited by this paper
• Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis

  2006cited by this paper
• Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus

  2005cited by this paper
• Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome

  2005cited by this paper
• Novel Inhalational Murine Model of Invasive Pulmonary Aspergillosis

  2004cited by this paper
• Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity.

  2004cited by this paper
• Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants.

  2004cited by this paper
• Combination antifungal therapy for invasive aspergillosis.

  2004cited by this paper
• Cyclophosphamide metabolism is affected by azole antifungals.

  2004cited by this paper
• Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.

  2004cited by this paper
• Invasive aspergillosis in critically ill patients without malignancy.

  2004cited by this paper
• The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy

  2003cited by this paper
• The Antifungal Echinocandin Caspofungin Acetate Kills Growing Cells of Aspergillus fumigatus In Vitro

  2002cited by this paper
• Antifungal Efficacy of Caspofungin (MK-0991) in Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits: Pharmacokinetics, Drug Disposition, and Relationship to Galactomannan Antigenemia

  2002cited by this paper
• Comparison of caspofungin and amphotericin B for invasive candidiasis.

  2002cited by this paper
• Aspergillosis case-fatality rate: systematic review of the literature.

  2001cited by this paper
• Quantitative PCR Assay To MeasureAspergillus fumigatus Burden in a Murine Model of Disseminated Aspergillosis: Demonstration of Efficacy of Caspofungin Acetate

  2001cited by this paper
• Development of two real-time quantitative TaqMan PCR assays to detect circulating Aspergillus fumigatus DNA in serum.

  2001cited by this paper
• Antifungal Efficacy, Safety, and Single-Dose Pharmacokinetics of LY303366, a Novel Echinocandin B, in Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits

  1998cited by this paper
• Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors

  1997cited by this paper
• Guide for the Care and Use of Laboratory Animals

  1996cited by this paper

• The Four Critical Priority Fungi According to the World Health Organization and the Hope for New Therapies: A Focus on Cell Wall Antifungal Targets

  2026cites this paper
• Preclinical Models for Cryptococcosis of the CNS and Their Characterization Using In Vivo Imaging Techniques

  2024cites this paper
• Candida albicans Infections: a novel porcine wound model to evaluate treatment efficacy

  2022cites this paper
• Our pursuit for effective antifungal agents targeting fungal cell wall components, where are we?

  2021cites this paper
• Caenorhabditis elegans-Based Aspergillus fumigatus Infection Model for Evaluating Pathogenicity and Drug Efficacy

  2020cites this paper
• Recent Progress in the Discovery of Antifungal Agents Targeting the Cell Wall.

  2020cites this paper
• Fungal Infections and ABPA

  2020cites this paper
• Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus

  2019cites this paper
• Bioactive Peptides Against Fungal Biofilms

  2019cites this paper
• In vitro and in vivo Efficacy of a Synergistic Combination of Itraconazole and Verapamil Against Aspergillus fumigatus

  2019cites this paper
• Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms

  2018cites this paper
• Systemic Antifungal Agents: Current Status and Projected Future Developments.

  2017cites this paper
• ECHINOCANDINS VERSUS DATED ANTIFUNGALS IN COMBINATION AGAINST OPPORTUNISTIC MYCOTIC INFECTIONS

  2017cites this paper
• Rodent Models of Invasive Aspergillosis due to Aspergillus fumigatus: Still a Long Path toward Standardization

  2017cites this paper
• Antifungals

  2017cites this paper
• A complex game of hide and seek: the search for new antifungals.

  2016cites this paper
• What's new in antifungals: an update on the in-vitro activity and in-vivo efficacy of new and investigational antifungal agents

  2015cites this paper
• Post-diagnostic kinetics of the (1 → 3)-β-D-glucan assay in invasive aspergillosis, invasive candidiasis and Pneumocystis jirovecii pneumonia.

  2012cites this paper